US.KVUE · Kenvue

{
  "risk": {
    "level": "Medium",
    "reason": "risk management score >= 6.5/10",
    "position": {
      "score": 1.6,
      "details": {
        "atrPct": 2.433703116745906,
        "turnoverUsdM": 335.18218986,
        "liquidityPoints": 0.6,
        "volatilityPoints": 1
      }
    },
    "rrPoints": 1.4,
    "stopLevels": {
      "symbol": "US.KVUE",
      "rr_range": "1:1.0-1:2.5",
      "risk_profile": "中等",
      "stop_loss_price": 18.0086,
      "strength_details": {
        "ma_score": 2,
        "atr_score": 2,
        "rsi_score": 1,
        "macd_score": 1,
        "volume_score": 1
      },
      "market_adjustment": 1,
      "risk_reward_ratio": 1,
      "stop_loss_percent": 4.9,
      "take_profit_price": 19.8765,
      "target_multiplier": 1.6,
      "technical_strength": 1.35,
      "take_profit_percent": 5
    },
    "positionPoints": 1.6,
    "stopLossPoints": 2.4,
    "diversification": {
      "score": 2,
      "details": {
        "method": "sector concentration proxy; no portfolio holdings used",
        "sector": "Consumer Staples",
        "concentratedSectorPenalty": 0
      }
    },
    "riskRewardRatio": 1.2,
    "stopLossPercent": 4.867406233491812,
    "diversificationPoints": 2
  },
  "total": {
    "max": 160,
    "result": 50.1,
    "formula": "score_with_momentum_v2 = main_score + momentum_5d_v2_score",
    "baseScore": 50.1,
    "modelVersion": "cursor_18_27_news_v2_160",
    "momentum5dScore": 0
  },
  "market": {
    "ma20": 19.23,
    "ma50": 19.0042,
    "close": 18.93,
    "prevClose": 19.13,
    "avgVolume20": 22178825,
    "volumeRatio": 0.8,
    "changePercent": -1.05
  },
  "sources": {
    "catalyst": "finnhub_news_keyword_model",
    "sentiment": "finnhub_news_keyword_model",
    "fundamentals": "fmp_stable",
    "institutional": null,
    "marketContext": "twelvedata+fred"
  },
  "barCount": 60,
  "momentum": {
    "max": 50,
    "result": 0,
    "details": {
      "ret_5d": -0.014062499999999978,
      "max_score": 50,
      "max_total": 50,
      "raw_total": 0,
      "vcp_bonus": 0,
      "vol_ratio": 0.8043233328192674,
      "ret_points": 0,
      "vol_points": 0,
      "range_ratio": 0.6663023689423353,
      "volat_points": 0,
      "day_range_pct": 0.015055467511885903,
      "model_version": "cursor_18_27_news_v2_160",
      "available_bars": 30,
      "breakout_points": 0,
      "partial_history": false,
      "pullback_points": 0,
      "breakout_vol_bonus": 0,
      "first_breakout_20d": false,
      "return_window_days": 5,
      "first_breakout_bonus": 0,
      "breakout_quality_points": 0
    },
    "formula": "Cursor_18.25 5D momentum v2 0-50",
    "modelVersion": "cursor_18_27_news_v2_160"
  },
  "scoreMax": 110,
  "composite": {
    "max": 160,
    "result": 50.1,
    "formula": "Cursor_18.25 ranking score v2 (score_with_momentum_v2)",
    "weights": [
      {
        "raw": 4.1,
        "label": "基本面",
        "weight": "5/110",
        "normalized": 82,
        "contribution": 4.1
      },
      {
        "raw": 9.2,
        "label": "資金流",
        "weight": "20/110",
        "normalized": 46,
        "contribution": 9.2
      },
      {
        "raw": 6.8,
        "label": "市場環境",
        "weight": "15/110",
        "normalized": 45.33,
        "contribution": 6.8
      },
      {
        "raw": 6,
        "label": "催化劑",
        "weight": "20/110",
        "normalized": 30,
        "contribution": 6
      },
      {
        "raw": 7.4,
        "label": "風險管理",
        "weight": "10/110",
        "normalized": 74,
        "contribution": 7.4
      },
      {
        "raw": 15.6,
        "label": "技術信號",
        "weight": "30/110",
        "normalized": 52,
        "contribution": 15.6
      },
      {
        "raw": 1,
        "label": "情緒分析",
        "weight": "10/110",
        "normalized": 10,
        "contribution": 1
      }
    ],
    "modelVersion": "cursor_18_27_news_v2_160"
  },
  "momentumMax": 50,
  "scoreStatus": "incomplete",
  "standard110": {
    "rating": "避免",
    "result": 50.1,
    "details": [
      "基本面分析總分: 4.1/5分",
      "資金流分析總分: 9.2/20分",
      "市場環境分析總分: 6.8/15分",
      "催化劑分析: 6/20分",
      "風險管理總分: 7.4/10分",
      "技術信號分析總分: 15.6/30分",
      "情緒分析: 1/10分",
      "共振率(僅顯示不加分): 0%"
    ],
    "formula": "基本面5 + 資金流20 + 市場環境15 + 催化劑20 + 風險管理10 + 技術信號30 + 情緒10",
    "dimensionScores": {
      "催化劑": 6,
      "基本面": 4.1,
      "資金流": 9.2,
      "市場環境": 6.8,
      "情緒分析": 1,
      "技術信號": 15.6,
      "風險管理": 7.4
    },
    "dimensionDetails": {
      "催化劑": {
        "max": 20,
        "grade": "較差",
        "items": {
          "catalyst": {
            "score": 6,
            "details": {
              "source": "finnhub_news_keyword_model",
              "articleCount": 7,
              "catalystCount": 1
            }
          },
          "catalystPoints": 6
        }
      },
      "基本面": {
        "max": 5,
        "grade": "優秀",
        "items": {
          "pbPoints": 0.4,
          "pePoints": 0.4,
          "epsPoints": 0.75,
          "roePoints": 0.6,
          "debtPoints": 0.4,
          "marginPoints": 0,
          "turnoverUsdM": 335.18218986,
          "volumePoints": 0.5,
          "revenuePoints": 0,
          "dividendPoints": 0.5,
          "marketCapPoints": 0.5
        },
        "source": "fmp_stable"
      },
      "資金流": {
        "max": 20,
        "grade": "較差",
        "items": {
          "cmfPoints": 2.4,
          "mfiPoints": 1.6,
          "obvPoints": 2.4,
          "vwapPoints": 0.8,
          "institutional": {
            "score": 2,
            "details": {
              "source": "optional-neutral",
              "warning": {
                "code": "INSTITUTIONAL_DATA_OPTIONAL",
                "symbol": "US.KVUE",
                "message": "Institutional ownership is unavailable; neutral 2/4 money-flow treatment used."
              },
              "optional": true,
              "holderCount": null,
              "holderPoints": 2,
              "top10ShareRatio": null,
              "concentrationPenalty": 0
            }
          },
          "institutionPoints": 2
        }
      },
      "市場環境": {
        "max": 15,
        "grade": "較差",
        "items": {
          "vix": {
            "score": 0,
            "details": {
              "source": "twelvedata+fred",
              "missing": true,
              "vixClose": null
            }
          },
          "trend": {
            "score": 3,
            "details": {
              "qqq": {
                "ma20": 707.7280003500002,
                "ma50": 713.0466018399998,
                "name": "QQQ",
                "close": 710.92999,
                "points": 1
              },
              "spy": {
                "ma20": 760.98750315,
                "ma50": 750.9438048,
                "name": "SPY",
                "close": 762.59998,
                "points": 2
              },
              "source": "twelvedata+fred"
            }
          },
          "atrPct": 2.433703116745906,
          "atrPoints": 3,
          "cciPoints": 0.8,
          "vixPoints": 0,
          "marketTrendPoints": 3
        }
      },
      "情緒分析": {
        "max": 10,
        "grade": "較差",
        "items": {
          "sentiment": {
            "score": 1,
            "details": {
              "source": "finnhub_news_keyword_model",
              "articleCount": 7,
              "negativeHits": 2,
              "positiveHits": 0,
              "sentimentScoreRaw": -0.7
            }
          },
          "sentimentData": {
            "raw": [
              {
                "id": 141140792,
                "url": "https://finnhub.io/api/news?id=318271c5d30e8dc8f0c9e7dc2705abc9a710b868399edd0e10a67b178b9c9a81",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "KVUE",
                "summary": "Kenvue posts higher Q2 sales and earnings, but both miss estimates as inflation, tariffs and foreign exchange pressure margins.",
                "category": "company",
                "datetime": 1786037880,
                "headline": "KVUE Q2 Earnings Miss Estimates as Margins Narrows, Sales Rise"
              },
              {
                "id": 141134272,
                "url": "https://finnhub.io/api/news?id=2a0e5b9435819d66aec13da0351ac61b45ff33178349359a162bf22a59f2e9f7",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "KVUE",
                "summary": "Kenvue (KVUE) delivered earnings and revenue surprises of -3.13% and -0.86%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?",
                "category": "company",
                "datetime": 1786018807,
                "headline": "Kenvue (KVUE) Lags Q2 Earnings and Revenue Estimates"
              },
              {
                "id": 141133412,
                "url": "https://finnhub.io/api/news?id=66c79f2d6aa62005a105fd6a0a79ee3b50fb42e53605da2a455ad55e344e1032",
                "image": "https://www.chartmill.com/images/uploads/THUMBNAILS_CHARTMILL_1000_528_17_c249efcc18.webp",
                "source": "ChartMill",
                "related": "KVUE",
                "summary": "Kenvue Q2 earnings and revenue miss estimates; shares dip as consumer health mixed amid pending Kimberly-Clark acquisition.",
                "category": "company",
                "datetime": 1786017377,
                "headline": "Kenvue (NYSE:KVUE) Falls After Q2 Earnings Miss as Kimberly-Clark Deal Looms"
              },
              {
                "id": 141021082,
                "url": "https://finnhub.io/api/news?id=3954e9aadbe5b0f63c0e39fff326486893abede0271e476219c2754ee54110ba",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "KVUE",
                "summary": "Kenvue recently received FDA approval for Tylenol with Naproxen, a new over-the-counter pain reliever offering up to 12 hours of pain relief and slated for distribution across major U.S. retailers. This product launch adds a differentiated option to Kenvue’s Self Care portfolio, potentially strengthening the Tylenol brand’s position in the competitive pain relief category. Next, we’ll examine how the FDA approval of Tylenol with Naproxen could influence Kenvue’s investment narrative and...",
                "category": "company",
                "datetime": 1785028176,
                "headline": "Tylenol With Naproxen FDA Approval Could Be A Game Changer For Kenvue (KVUE)"
              },
              {
                "id": 141021083,
                "url": "https://finnhub.io/api/news?id=e8b60e0ae9f99398481ebddf7e76f9aa87d728595fc8f4211cfd6f86f4aa183c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "KVUE",
                "summary": "Kenvue stock has delivered a decline of 11.7% over the past year, yet the current Discounted Cash Flow (DCF) intrinsic value estimate indicates the shares may trade at a sizeable discount to that model, while market based multiples look closer to fair. Over the past 12 months, Kenvue is down 11.7%, which puts recent gains into context as a recovery rather than a clear winning streak. Investor expectations for the consumer health portfolio and cash flow resilience can support the DCF view of...",
                "category": "company",
                "datetime": 1785024986,
                "headline": "Is Kenvue (KVUE) Stock A Bargain With Lawsuits Back In Focus?"
              },
              {
                "id": 141016949,
                "url": "https://finnhub.io/api/news?id=570bb201fa1bcfd0eb77452f1948d521c96cf580598a0390815317a0edf9a1ca",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "KVUE",
                "summary": "The FDA’s approval of Tylenol with Naproxen, a new over the counter pain reliever offering up to 12 hours of relief, has put Kenvue (KVUE) in focus after the stock gained about 2%. See our latest analysis for Kenvue. The FDA decision appears to have added to existing momentum in Kenvue’s stock, with a 90 day share price return of 10.23% and an 11.32% year to date share price return, even though the 1 year total shareholder return is down 11.67%. If this kind of news driven move has you...",
                "category": "company",
                "datetime": 1784992514,
                "headline": "Kenvue (KVUE) Gets An FDA Lift On Tylenol As Valuation Looks Tight"
              },
              {
                "id": 141010898,
                "url": "https://finnhub.io/api/news?id=b3e578862102b9d8a7daac60ef49dd6b4518e2cd4d213c63c27ac74b4ecf50cb",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "KVUE",
                "summary": "The newly approved product is the first and only fixed-dose combination of acetaminophen and naproxen sodium available without a prescription.",
                "category": "company",
                "datetime": 1784925776,
                "headline": "KVUE Stock Rises As FDA Approves Tylenol Combination Despite Trump Administration’s Pushback"
              }
            ],
            "raw_source": [
              {
                "id": 141261729,
                "url": "https://finnhub.io/api/news?id=c88cc7e7cc91f6d0020d7de624a2c351fd92acbfd3808ec26302e04d766c0a55",
                "image": "",
                "source": "Benzinga",
                "related": "KVUE",
                "summary": "https://www.essity.com/media/press-release/essity-acquires-feminine-care-business-in-brazil/9dd724cebbb532f5/",
                "category": "company",
                "datetime": 1787144784,
                "headline": "Essity Strikes Agreement To Acquire Kenvue's Feminine Care Operations In Brazil For $284M"
              },
              {
                "id": 141217703,
                "url": "https://finnhub.io/api/news?id=12de485133966863736ada6379090d41e2c92768a4b0512f9d46356884a13179",
                "image": "",
                "source": "Benzinga",
                "related": "KVUE",
                "summary": "- Reuters ",
                "category": "company",
                "datetime": 1786710903,
                "headline": "South Africa's Competition Tribunal Says Deal Between Kimberly-Clark Corporation And Kenvue Approved With Conditions"
              },
              {
                "id": 141215528,
                "url": "https://finnhub.io/api/news?id=74bcdf075cf3a7f5241aae00593ab560da48aec4024d0dd78a861672eaa4d254",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "KVUE",
                "summary": "Personal care products provider Kimberly-Clark Corporation (NYSE:KMB)’s shares are down by 17% over the past year and are up by 9% year-to-date. It is currently undergoing a major transformation through acquiring Kenvue. Cramer has discussed Kimberly-Clark Corporation (NYSE:KMB)’s acquisition several times and linked its performance with consumer goods giant Procter & Gamble. In his morning […]",
                "category": "company",
                "datetime": 1786694517,
                "headline": "Jim Cramer Said Kimberly-Clark Corporation (NYSE:KMB) + Kenvue Could Take On P&G – But Is He Right?"
              },
              {
                "id": 141205703,
                "url": "https://finnhub.io/api/news?id=159108e90cdd7f4ecef85c2c3fa07bcd7889d5cafe7e450000dc2465f71907dc",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "KVUE",
                "summary": "Kimberly-Clark Corporation (NASDAQ: KMB) today announced the appointment of Suzana Blades as Senior Vice President and General Counsel, effective September 1, 2026. She will report to Jeff Melucci, Chief Strategy, Business Development and Administrative Officer, and will become a member of Kimberly-Clark's Executive Leadership Team.",
                "category": "company",
                "datetime": 1786627500,
                "headline": "Kimberly-Clark Appoints Suzana Blades as Senior Vice President and General Counsel"
              },
              {
                "id": 141202291,
                "url": "https://finnhub.io/api/news?id=76d517a10585cab2c26f64a1e56e8cb30a507d567723c96c47cc86eec4a2f371",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "KVUE",
                "summary": "KVUE's Q2 sales and earnings miss estimates, but organic growth improved as Skin Health and Beauty led a broader recovery.",
                "category": "company",
                "datetime": 1786555860,
                "headline": "Kenvue Q2 Deep Dive: Assessing Financial Metrics & Growth Prospects"
              },
              {
                "id": 141192992,
                "url": "https://finnhub.io/api/news?id=300243f926ab59a86564b109878e1e9a1298e5fbdd0e3a9d1b41c2dc345f4ae9",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/487834119/image_487834119.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "KVUE",
                "summary": "Kimberly-Clark looks good, supported by a strong innovation pipeline, international growth, and the Kenvue acquisition. See why I rate KMB stock a Buy.",
                "category": "company",
                "datetime": 1786529421,
                "headline": "Kimberly-Clark: Temporary Headwinds, Strong Innovation And Kenvue Synergies Support A Buy"
              },
              {
                "id": 141190121,
                "url": "https://finnhub.io/api/news?id=6122dcbbe887770943e505b8e118b1a6814c928f257ef65b6a02dcccc21b63a2",
                "image": "",
                "source": "SeekingAlpha",
                "related": "KVUE",
                "summary": "",
                "category": "company",
                "datetime": 1786485283,
                "headline": "Tracking AMG's Yacktman Asset Management Portfolio - Q2 2026 Update"
              },
              {
                "id": 141197679,
                "url": "https://finnhub.io/api/news?id=ba6a24e91c59e9e5a733c345d867f673e857d079db042d4aeadb40eeefae14a8",
                "image": "",
                "source": "Benzinga",
                "related": "KVUE",
                "summary": "UBS  analyst Peter Grom   maintains Kenvue (NYSE:KVUE) with a Neutral and lowers the price target from $20 to $19.",
                "category": "company",
                "datetime": 1786467602,
                "headline": "UBS Maintains Neutral on Kenvue, Lowers Price Target to $19"
              },
              {
                "id": 141184813,
                "url": "https://finnhub.io/api/news?id=c8fff2e1135db913b49c4288b3803f729e59553ba605f811ab444cbc07d6ab7b",
                "image": "https://cdn.benzinga.com/files/images/story/2026/08/11/Policy-Changes-Add-Pressure.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "KVUE",
                "summary": "President Donald Trump signed an order Monday limiting core childhood vaccine recommendations to 11 vaccines.",
                "category": "company",
                "datetime": 1786402887,
                "headline": "Trump Cuts Core Childhood Vaccine Recommendations to 11, Bill Cassidy Says 'This Executive Order Is Wrong'"
              },
              {
                "id": 141147223,
                "url": "https://finnhub.io/api/news?id=e2f6c6d84259b73ba43c9552d7e811cb9de4f2173ba5b71184a8f7dbc784932a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "KVUE",
                "summary": "Kenvue just snapped a four-quarter earnings streak while Reddit falls nearly silent, and the reason why tells you everything about where this stock goes next.",
                "category": "company",
                "datetime": 1786106715,
                "headline": "How Reddit and Wall Street See Kenvue as Buyout Nears"
              },
              {
                "id": 141149233,
                "url": "https://finnhub.io/api/news?id=31c0dfc6eeb2fb4393ccddf6608e7c5855ec88bafabad5b9b0160b74c906d044",
                "image": "https://cdn.benzinga.com/files/images/story/2026/08/07/January-29--2025---Washington-Dc-Senate-.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "KVUE",
                "summary": "The Trump administration is reportedly considering an executive order on vaccines and autism as early as next week.",
                "category": "company",
                "datetime": 1786091773,
                "headline": "Trump Administration Reportedly Weighs Executive Order on Autism and Vaccines Days After RFK Jr. Hinted At 'Certain Interventions'"
              },
              {
                "id": 141140791,
                "url": "https://finnhub.io/api/news?id=2915bb4bab3bafa5b0d1ff814514673bf262512ed5ed71c7218276d1cee2ad9f",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "KVUE",
                "summary": "Sales and earnings increased across Kenvue's portfolio, but tariffs, inflation and currency costs reduced profitability.",
                "category": "company",
                "datetime": 1786046330,
                "headline": "Kenvue Stock Falls 2.7% as Growth Arrives With Thinner Margins"
              },
              {
                "id": 141140792,
                "url": "https://finnhub.io/api/news?id=318271c5d30e8dc8f0c9e7dc2705abc9a710b868399edd0e10a67b178b9c9a81",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "KVUE",
                "summary": "Kenvue posts higher Q2 sales and earnings, but both miss estimates as inflation, tariffs and foreign exchange pressure margins.",
                "category": "company",
                "datetime": 1786037880,
                "headline": "KVUE Q2 Earnings Miss Estimates as Margins Narrows, Sales Rise"
              },
              {
                "id": 141135705,
                "url": "https://finnhub.io/api/news?id=caee65f50e1794077c538ed53aa7eb04dee45519a3a6cb7940bcc40ba8071d4d",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "KVUE",
                "summary": "Kenvue Inc (NYSE:KVUE) shares fell about 2% on Thursday after the consumer health company reported second quarter results that narrowly missed Wall Street expectations, while margins declined from a year earlier. The company reported adjusted diluted earnings per share of $0.31, compared with...",
                "category": "company",
                "datetime": 1786030260,
                "headline": "Kenvue second quarter results fall short of expectations, sending shares lower"
              },
              {
                "id": 141134272,
                "url": "https://finnhub.io/api/news?id=2a0e5b9435819d66aec13da0351ac61b45ff33178349359a162bf22a59f2e9f7",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "KVUE",
                "summary": "Kenvue (KVUE) delivered earnings and revenue surprises of -3.13% and -0.86%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?",
                "category": "company",
                "datetime": 1786018807,
                "headline": "Kenvue (KVUE) Lags Q2 Earnings and Revenue Estimates"
              },
              {
                "id": 141133412,
                "url": "https://finnhub.io/api/news?id=66c79f2d6aa62005a105fd6a0a79ee3b50fb42e53605da2a455ad55e344e1032",
                "image": "https://www.chartmill.com/images/uploads/THUMBNAILS_CHARTMILL_1000_528_17_c249efcc18.webp",
                "source": "ChartMill",
                "related": "KVUE",
                "summary": "Kenvue Q2 earnings and revenue miss estimates; shares dip as consumer health mixed amid pending Kimberly-Clark acquisition.",
                "category": "company",
                "datetime": 1786017377,
                "headline": "Kenvue (NYSE:KVUE) Falls After Q2 Earnings Miss as Kimberly-Clark Deal Looms"
              },
              {
                "id": 141133334,
                "url": "https://finnhub.io/api/news?id=b991a9a6f55b83499acecfc65176f9d762825ca8c7c188e203b55f4c84ee7323",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "KVUE",
                "summary": "US equity markets were mostly pointing higher before the opening bell Thursday as investors assess p",
                "category": "company",
                "datetime": 1786017164,
                "headline": "Stocks Mostly Up Pre-Bell as Investors Weigh Potential Iran-Oman Hormuz Deal, Await More Earnings"
              },
              {
                "id": 141133375,
                "url": "https://finnhub.io/api/news?id=908f5ecdcad023d2670788b091315d4dc6bd45365751dddd3cd78cd32d04e1da",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "KVUE",
                "summary": "SUMMIT, N.J., August 06, 2026--Kenvue Inc. (NYSE: KVUE) today announced financial results for the fiscal second quarter ended June 28, 2026.",
                "category": "company",
                "datetime": 1786013100,
                "headline": "Kenvue Reports Second Quarter 2026 Results"
              },
              {
                "id": 141124434,
                "url": "https://finnhub.io/api/news?id=0b2c7c7a5963a0ed93f4046ae18f65b4d7324cb035df75fa98e2c21c0f88d7d0",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "KVUE",
                "summary": "Kimberly-Clark's (KMB) Q2 earnings beat showed the company can deliver steady profit growth despite",
                "category": "company",
                "datetime": 1785951351,
                "headline": "Kimberly-Clark Delivers Solid Q2 Despite Sales Headwinds, RBC Says"
              },
              {
                "id": 141110929,
                "url": "https://finnhub.io/api/news?id=640b47fa8b821e15942b5c6029c858dabdc34b08ea748ae956248cd7c10ccdea",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1215561374/image_1215561374.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "KVUE",
                "summary": "Kimberly-Clark Corporation Q2 analysis: Mixed results, unsustainable profit boosts, and weak FY guidance. Click for this KMB stock update.",
                "category": "company",
                "datetime": 1785848646,
                "headline": "Kimberly-Clark Q2 Earnings: More Challenges, But The Market Is Looking Elsewhere"
              },
              {
                "id": 141108878,
                "url": "https://finnhub.io/api/news?id=49bab789a4b7311555e0f5eae3cec7667e88d3f627770d607b2c44705153d292",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "KVUE",
                "summary": "Kimberly-Clark stock has fallen 15.9% over the past year, yet an intrinsic value estimate based on a Discounted Cash Flow (DCF) approach currently points to the shares trading at a sizeable discount to that estimate, while broader checks and earnings multiples suggest something closer to a fair price. The 15.9% share price decline over the last 12 months reflects weaker recent returns, which can matter if the market is reassessing Kimberly-Clark’s prospects. The planned acquisition of...",
                "category": "company",
                "datetime": 1785845562,
                "headline": "Kimberly Clark (KMB) Stock Looks Below Fair Value As Shares Fell 16%"
              },
              {
                "id": 141081692,
                "url": "https://finnhub.io/api/news?id=30ca5e3e530ef309da7cd41b174ea9ce0b24e11c3c7fe8f11fc4446e7e87381a",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "KVUE",
                "summary": "KVUE is expected to post Q2 revenue and earnings growth as brand strength, innovation and productivity efforts offset seasonal and cost pressures.",
                "category": "company",
                "datetime": 1785518520,
                "headline": "Kenvue's Q2 Earnings Coming Up: Here's What Lies Ahead of the Stock"
              },
              {
                "id": 141078091,
                "url": "https://finnhub.io/api/news?id=b11e0ec14791d62bd98a0fff1b55701adb6ffc8624f51e2808ef2aa706ecc9a7",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "KVUE",
                "summary": "Church & Dwight (CHD) delivered earnings and revenue surprises of 0.00% and +1.79%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?",
                "category": "company",
                "datetime": 1785499502,
                "headline": "Church & Dwight (CHD) Meets Q2 Earnings Estimates"
              },
              {
                "id": 141054091,
                "url": "https://finnhub.io/api/news?id=373e39fcc810642bfaa15338748453153259c83e0ab70ada8c058c2a28fd3eea",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "KVUE",
                "summary": "KVUE's trusted brands, margin gains and pending Kimberly-Clark deal shape its outlook amid mixed growth signals.",
                "category": "company",
                "datetime": 1785335880,
                "headline": "Kenvue's Brand Strength and Growth Drivers Shape Its Future Outlook"
              },
              {
                "id": 141054092,
                "url": "https://finnhub.io/api/news?id=ab1fc595f65aff0d46ab053b8a8969d2a80149e3db8c932af7170e4eb3a1e791",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "KVUE",
                "summary": "KVUE's margin gains and stronger cash flow boost its appeal, but slow organic growth, debt and deal uncertainty keep the outlook balanced.",
                "category": "company",
                "datetime": 1785335820,
                "headline": "Is Kenvue Stock Attractive After Margin Gains and Deal Uncertainty"
              },
              {
                "id": 141054399,
                "url": "https://finnhub.io/api/news?id=11fc9ce506f2a0bec926f7f22776292db527e98a7a1d96c20c82ef1fbc67c709",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "KVUE",
                "summary": "Kenvue's beauty momentum, margin expansion and stronger cash flow support its outlook as uneven demand and deal uncertainty temper visibility.",
                "category": "company",
                "datetime": 1785335760,
                "headline": "Kenvue Benefits From Consumer Health Trends and Margin Expansion"
              },
              {
                "id": 141052250,
                "url": "https://finnhub.io/api/news?id=ca0613044d5975b18d24b83dbc31cb9208aab497eb4eddd8565489ac141c261e",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "KVUE",
                "summary": "SUMMIT, N.J., July 29, 2026--Kenvue Inc. (NYSE: KVUE) today announced that its Board of Directors declared a quarterly dividend of $0.21 per share on its common stock, which represents a 1.2 percent increase compared to the prior quarterly dividend. The quarterly dividend is payable on August 26, 2026, to shareholders of record as of the close of business on August 12, 2026.",
                "category": "company",
                "datetime": 1785321900,
                "headline": "Kenvue Increases Quarterly Cash Dividend"
              },
              {
                "id": 141054400,
                "url": "https://finnhub.io/api/news?id=098c5e64880b72b99cc21958fa08d2e1d22ea28c5dc14ca98f4f6feb545f1571",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "KVUE",
                "summary": "Kenvue has lagged the broader market over the past year, leaving analysts with a measured view on the stock.",
                "category": "company",
                "datetime": 1785314879,
                "headline": "What Are Wall Street Analysts' Target Price for Kenvue Stock?"
              },
              {
                "id": 141062384,
                "url": "https://finnhub.io/api/news?id=f15615f98ee3eec991d639a53cd40d9c6b274f10a2600a96a272fe05362e998d",
                "image": "",
                "source": "Benzinga",
                "related": "KVUE",
                "summary": "The quarterly dividend is payable on August 26, 2026, to shareholders of record as of the close of business on August 12, 2026.",
                "category": "company",
                "datetime": 1785307613,
                "headline": "Kenvue Increases Quarterly Dividend By 1.2% To $0.21 Per Share"
              },
              {
                "id": 141048146,
                "url": "https://finnhub.io/api/news?id=6bb82aad805c6a173e46be241afba15536fff4a89d414816e0eb8f701add24ee",
                "image": "https://cdn.benzinga.com/files/images/story/2026/07/28/Johnson--Johnson-Inc--JNJ.jpg?width=2048&height=1536",
                "source": "Benzinga",
                "related": "KVUE",
                "summary": "Johnson & Johnson reached a $5.5 billion agreement to resolve remaining federal and state talc litigation over ovarian cancer claims.",
                "category": "company",
                "datetime": 1785233415,
                "headline": "Johnson & Johnson Puts 15-Year Meritless Talc Litigation To Rest"
              },
              {
                "id": 141032930,
                "url": "https://finnhub.io/api/news?id=d870ed4d287c76d4d95b71bb84ebee653b237c80632e7985dae979065861a7d0",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "KVUE",
                "summary": "Black Monday wiped out 22% of the market in a single day, and most investors never saw it coming. A small group of companies not only survived that crash and every major meltdown since, but kept sending bigger checks to shareholders each time the panic peaked.",
                "category": "company",
                "datetime": 1785154810,
                "headline": "5 Dividend Kings Continued to Pay and Raise Dividends Through Every Market Crash Since Black Monday"
              },
              {
                "id": 141028474,
                "url": "https://finnhub.io/api/news?id=9a2687b22714d8cedc636831b2bc62592056cb84c4baeb1b206ee7ea9c167dc4",
                "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2209914068/image_2209914068.jpg?io=getty-c-w1536",
                "source": "SeekingAlpha",
                "related": "KVUE",
                "summary": "Dividend Kings beat SPY in June–July, reclaiming a YTD lead.",
                "category": "company",
                "datetime": 1785093714,
                "headline": "Best Dividend Kings: July 2026"
              },
              {
                "id": 141021082,
                "url": "https://finnhub.io/api/news?id=3954e9aadbe5b0f63c0e39fff326486893abede0271e476219c2754ee54110ba",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "KVUE",
                "summary": "Kenvue recently received FDA approval for Tylenol with Naproxen, a new over-the-counter pain reliever offering up to 12 hours of pain relief and slated for distribution across major U.S. retailers. This product launch adds a differentiated option to Kenvue’s Self Care portfolio, potentially strengthening the Tylenol brand’s position in the competitive pain relief category. Next, we’ll examine how the FDA approval of Tylenol with Naproxen could influence Kenvue’s investment narrative and...",
                "category": "company",
                "datetime": 1785028176,
                "headline": "Tylenol With Naproxen FDA Approval Could Be A Game Changer For Kenvue (KVUE)"
              },
              {
                "id": 141021083,
                "url": "https://finnhub.io/api/news?id=e8b60e0ae9f99398481ebddf7e76f9aa87d728595fc8f4211cfd6f86f4aa183c",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "KVUE",
                "summary": "Kenvue stock has delivered a decline of 11.7% over the past year, yet the current Discounted Cash Flow (DCF) intrinsic value estimate indicates the shares may trade at a sizeable discount to that model, while market based multiples look closer to fair. Over the past 12 months, Kenvue is down 11.7%, which puts recent gains into context as a recovery rather than a clear winning streak. Investor expectations for the consumer health portfolio and cash flow resilience can support the DCF view of...",
                "category": "company",
                "datetime": 1785024986,
                "headline": "Is Kenvue (KVUE) Stock A Bargain With Lawsuits Back In Focus?"
              },
              {
                "id": 141016949,
                "url": "https://finnhub.io/api/news?id=570bb201fa1bcfd0eb77452f1948d521c96cf580598a0390815317a0edf9a1ca",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "KVUE",
                "summary": "The FDA’s approval of Tylenol with Naproxen, a new over the counter pain reliever offering up to 12 hours of relief, has put Kenvue (KVUE) in focus after the stock gained about 2%. See our latest analysis for Kenvue. The FDA decision appears to have added to existing momentum in Kenvue’s stock, with a 90 day share price return of 10.23% and an 11.32% year to date share price return, even though the 1 year total shareholder return is down 11.67%. If this kind of news driven move has you...",
                "category": "company",
                "datetime": 1784992514,
                "headline": "Kenvue (KVUE) Gets An FDA Lift On Tylenol As Valuation Looks Tight"
              },
              {
                "id": 141010898,
                "url": "https://finnhub.io/api/news?id=b3e578862102b9d8a7daac60ef49dd6b4518e2cd4d213c63c27ac74b4ecf50cb",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "KVUE",
                "summary": "The newly approved product is the first and only fixed-dose combination of acetaminophen and naproxen sodium available without a prescription.",
                "category": "company",
                "datetime": 1784925776,
                "headline": "KVUE Stock Rises As FDA Approves Tylenol Combination Despite Trump Administration’s Pushback"
              },
              {
                "id": 141009058,
                "url": "https://finnhub.io/api/news?id=7e3e1e371a19b270bdd4a967ba39ae684911a9e1c2808cce8205c9d0e7ab8f36",
                "image": "",
                "source": "Benzinga",
                "related": "KVUE",
                "summary": "TYLENOL® with Naproxen is a clinically proven, opioid-free, fixed-dose combination that begins working in under 30 minutes and provides 12 hours of pain relief in a single dose.FDA-approved first and only OTC fixed‑dose",
                "category": "company",
                "datetime": 1784901935,
                "headline": "FDA Approves Kenvue’s TYLENOL With Naproxen, OTC Fixed-Dose Combination Of Acetaminophen And Naproxen Sodium"
              },
              {
                "id": 141005278,
                "url": "https://finnhub.io/api/news?id=101d57aad953e5f98a330ef27d7ba5c285a1af9a27e27bfc8b6dd584d78b6aa2",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "KVUE",
                "summary": "On Tuesday’s episode of CNBC’s Mad Money, Jim Cramer highlighted Kimberly-Clark Corporation (NYSE:KMB) as a defensive holding for investors looking to lock in profits from high-flying technology stocks and reallocate into lower-risk value plays. After years of sluggish price action, Cramer noted that the consumer giant has finally established a stable bottom, anchored by a […]",
                "category": "company",
                "datetime": 1784895731,
                "headline": "Jim Cramer Says Kimberly-Clark’s Acquisition of Kenvue Creates a High-Margin Powerhouse"
              },
              {
                "id": 141009059,
                "url": "https://finnhub.io/api/news?id=9235f40a2e7b60e6c9500950aa681aa3c8213d91e5d2a5aba5de966cef163a69",
                "image": "",
                "source": "Benzinga",
                "related": "KVUE",
                "summary": "https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-first-nonprescription-fixed-dose-combination-acetaminophen-and-naproxen-sodium-12-hour",
                "category": "company",
                "datetime": 1784890198,
                "headline": "FDA Approves First Nonprescription Fixed-Dose Combination Of Acetaminophen, Naproxen Sodium For 12-Hour Pain Relief"
              },
              {
                "id": 140992633,
                "url": "https://finnhub.io/api/news?id=c01b01860f8db055364a814e9521def9f2b01ae18e77753ca907627437ff1ed6",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "KVUE",
                "summary": "SUMMIT, N.J., July 23, 2026--Kenvue Inc. (NYSE: KVUE) will announce its second quarter 2026 financial results before the market opens on August 6, 2026. Due to the pending transaction with Kimberly-Clark, Kenvue will not be hosting a quarterly conference call to review its financial results.",
                "category": "company",
                "datetime": 1784803500,
                "headline": "Kenvue to Announce Second Quarter 2026 Results on August 6, 2026"
              },
              {
                "id": 140973567,
                "url": "https://finnhub.io/api/news?id=76701072cf2fb47a5d34f32cec97c0f7678ae8fbee737c44fede042d9144ff06",
                "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
                "source": "Yahoo",
                "related": "KVUE",
                "summary": "Kenvue heads into its second-quarter earnings release with analysts projecting low double-digit EPS growth.",
                "category": "company",
                "datetime": 1784630702,
                "headline": "What to Expect From Kenvue’s Q2 2026 Earnings Report"
              },
              {
                "id": 140977494,
                "url": "https://finnhub.io/api/news?id=fb71116732f86abd864fa15a78d1ae46e2abb100b8dfc9cf2fcc7154eaaf7241",
                "image": "",
                "source": "Benzinga",
                "related": "KVUE",
                "summary": "Barclays  analyst Lauren Lieberman   maintains Kenvue (NYSE:KVUE) with a Equal-Weight and raises the price target from $18 to $19.",
                "category": "company",
                "datetime": 1784625659,
                "headline": "Barclays Maintains Equal-Weight on Kenvue, Raises Price Target to $19"
              }
            ],
            "data_source": "finnhub_news_keyword_model",
            "article_count": 7,
            "negative_hits": 2,
            "positive_hits": 0,
            "recomputed_at_score": true,
            "sentiment_score_raw": -0.7,
            "source_article_count": 42,
            "discarded_article_count": 35
          },
          "sentimentPoints": 1
        }
      },
      "技術信號": {
        "max": 30,
        "raw": 15.6,
        "grade": "較差",
        "items": {
          "bbPoints": 2.4,
          "adxPoints": 3,
          "sarPoints": 1.2000000000000002,
          "vcpPoints": 0.9,
          "macdPoints": 0.8,
          "vcpPayload": {
            "vcp_pass": false,
            "vcp_score": 0.9,
            "vcp_reason": "靠近20日高位；升放量(近10日2日)；Ready=N；Confirm=N",
            "vcp_metrics": {
              "up_days": 5,
              "vol_ref": 20736886.666666668,
              "down_days": 3,
              "vcp_ready": false,
              "above_ma50": false,
              "avg_vol_10": 20609620,
              "avg_vol_20": 22014035,
              "avg_vol_30": 20736886.666666668,
              "range_pct_10": 0.055467511885895444,
              "range_pct_20": 0.07374537770734288,
              "range_pct_30": 0.07744321183306926,
              "up_expand_ok": true,
              "lookback_used": 59,
              "near_20d_high": true,
              "contraction_ok": false,
              "down_shrink_ok": false,
              "up_expand_days": 2,
              "breakout_20d_ok": false,
              "vol_ratio_10_30": 0.9938627881459543,
              "dist_to_20d_high": 0.05567195450463931,
              "down_shrink_days": 1,
              "breakout_level_20d": 20.046,
              "vcp_breakout_confirm": false,
              "contraction_ratio_10_30": 0.7162346521145975
            },
            "vcp_name_en": "Volatility Contraction Pattern",
            "vcp_name_zh": "波動收縮形態",
            "vol_contraction": false
          },
          "kdjAdxPoints": 0.7,
          "rsiKdjPoints": 2.4,
          "volumeWeight": 2,
          "maCrossPoints": 2.4,
          "shortRsiPoints": 0.4,
          "shortMacdPoints": 0.4,
          "volConfirmPoints": 0.6,
          "volumePointsTechnical": 0.4
        }
      },
      "風險管理": {
        "max": 10,
        "grade": "良好",
        "items": {
          "position": {
            "score": 1.6,
            "details": {
              "atrPct": 2.433703116745906,
              "turnoverUsdM": 335.18218986,
              "liquidityPoints": 0.6,
              "volatilityPoints": 1
            }
          },
          "rrPoints": 1.4,
          "stopLevels": {
            "symbol": "US.KVUE",
            "rr_range": "1:1.0-1:2.5",
            "risk_profile": "中等",
            "stop_loss_price": 18.0086,
            "strength_details": {
              "ma_score": 2,
              "atr_score": 2,
              "rsi_score": 1,
              "macd_score": 1,
              "volume_score": 1
            },
            "market_adjustment": 1,
            "risk_reward_ratio": 1,
            "stop_loss_percent": 4.9,
            "take_profit_price": 19.8765,
            "target_multiplier": 1.6,
            "technical_strength": 1.35,
            "take_profit_percent": 5
          },
          "positionPoints": 1.6,
          "stopLossPoints": 2.4,
          "diversification": {
            "score": 2,
            "details": {
              "method": "sector concentration proxy; no portfolio holdings used",
              "sector": "Consumer Staples",
              "concentratedSectorPenalty": 0
            }
          },
          "riskRewardRatio": 1.2,
          "stopLossPercent": 4.867406233491812,
          "diversificationPoints": 2
        }
      }
    }
  },
  "modelVersion": "cursor_18_27_news_v2_160",
  "providerErrors": [
    {
      "code": "VIX_MISSING",
      "symbol": "US.KVUE",
      "message": "VIX market context is required for market environment scoring",
      "missing": [
        "VIX"
      ],
      "provider": "scoring"
    }
  ],
  "rankingScoreMax": 160,
  "dataCompleteness": {
    "complete": false,
    "missingFields": [
      "VIX"
    ],
    "optionalInputs": [
      "institutionalData"
    ],
    "requiredInputs": [
      "fundamentals",
      "marketContext.VIX",
      "marketContext.SPY",
      "marketContext.QQQ",
      "catalystData",
      "sentimentData",
      "ATR",
      "sector"
    ],
    "optionalInputWarnings": []
  },
  "technicalIndicators": {
    "adx": 92.86,
    "atr": {
      "atr": 0.4607,
      "rule": "ATR / current price; lower volatility scores higher",
      "score": 6,
      "atr_pct": 2.43
    },
    "cci": {
      "rule": "Cursor_18.24 CCI bands",
      "level": "超買或超賣風險",
      "score": 2,
      "value": -74.03
    },
    "cmf": {
      "rule": "Cursor_18.24 CMF bands",
      "level": "輕微流入",
      "score": 6,
      "value": 0.1545
    },
    "kdj": {
      "d": 39.75,
      "j": 48.51,
      "k": 42.67,
      "rule": "Cursor_18.24 K/D cross",
      "score": 4,
      "signal": "金叉"
    },
    "mfi": {
      "rule": "Cursor_18.24 MFI bands",
      "level": "弱流入",
      "score": 4,
      "value": 46.3
    },
    "obv": {
      "rule": "Cursor_18.24 recent_slope vs previous_slope",
      "score": 6,
      "trend": "有流入",
      "value": 108355398,
      "recentSlope": 928189.8,
      "previousSlope": 3891920
    },
    "rsi": 44.64,
    "sar": {
      "rule": "Cursor_18.24 Parabolic SAR",
      "score": 4,
      "trend": "下降",
      "value": 19.5656,
      "position": "SAR喺價上",
      "distancePct": 3.36,
      "previousTrend": "下降"
    },
    "ma50": 19.0042,
    "macd": {
      "macd": -0.017807641877158886,
      "trend": "看跌",
      "signal": 0.041506140099467154,
      "histogram": -0.05931378197662604
    },
    "vwap": {
      "rule": "Cursor_18.24 VWAP 20D consecutive close",
      "score": 2,
      "value": 19.209,
      "position": "<VWAP",
      "consecutiveAbove": 0
    },
    "volume": {
      "rule": "Cursor_18.24 volume ratio",
      "level": "空升",
      "ratio": 0.8,
      "score": 2,
      "avgVolume": 22178825,
      "currentVolume": 17706402
    },
    "derived": {
      "ma20": 19.23,
      "ma50": 19.0042,
      "prevClose": 19.13,
      "avgVolume10": 19847410,
      "avgVolume20": 22178825,
      "changePercent": -1.05,
      "avgVolumeForScore": 22178825
    },
    "ma_cross": {
      "ma20": 19.23,
      "ma50": 19.0042,
      "rule": "Cursor_18.24 MA20/MA50 cross",
      "cross": "接近",
      "score": 6,
      "prevMa20": 19.2285,
      "prevMa50": 18.984,
      "spreadPct": 1.19,
      "isVolumeBreakout": false
    },
    "bollinger": {
      "lower": 18.6612,
      "upper": 19.7988,
      "position": "中間"
    },
    "rsi_short": 47.86,
    "macd_short": {
      "macd": 0,
      "trend": "中性",
      "signal": 0,
      "histogram": 0
    },
    "volume_ratio": {
      "ratio": 0.8
    }
  }
}

{
  "close": 18.93,
  "volume": 17706402,
  "changePercent": -1.05
}